ImmunityBio Faces Escalating Investor Lawsuit Over Drug Claims

The biotechnology firm ImmunityBio finds itself at the center of a growing class-action lawsuit, with its legal challenges intensifying following public statements made by its founder about a key cancer drug. The core allegation is that investors were misled regarding the capabilities of the therapy Anktiva.

Regulatory Rebuke and Stock Plunge

The situation escalated significantly after the U.S. Food and Drug Administration (FDA) issued a warning letter on March 13, 2026. The agency took issue with promotional claims made during a January 19, 2026 appearance by founder Patrick Soon-Shiong on The Sean Spicer Show, a YouTube podcast. In the episode titled "Is the FDA BLOCKING Life Saving Cancer Treatments?", Soon-Shiong suggested Anktiva could "treat virtually all cancers," despite its approval being specifically for a certain form of non-muscle invasive bladder cancer in combination with BCG.

The FDA determined that both the podcast interview and a television commercial created a misleading impression that the drug could generally cure or prevent cancer. The regulator noted that similar communication issues had been raised with the company internally before, indicating the letter was not unexpected.

When this regulatory action became public on March 24, 2026, the market reaction was severe. ImmunityBio's stock price collapsed by 21% in a single trading session, erasing approximately $2 billion in market capitalization.

Legal Machinery Gains Momentum

This event, combined with an earlier stock decline, now forms the foundation for a securities class action. The lawsuit, filed under the Securities Exchange Act of 1934, is proceeding as Douglas v. ImmunityBio, Inc. in the U.S. District Court for the Central District of California.

Plaintiffs allege that ImmunityBio and Soon-Shiong harmed investors by making materially misleading statements about Anktiva's potential. A consortium of seven law firms, including Pomerantz LLP, Rosen Law Firm, and Robbins Geller Rudman & Dowd, is actively seeking a lead plaintiff by a deadline of May 26, 2026. The full legal process is expected to extend far beyond this date.

The earlier stock drop occurred on January 23, 2026, when the company released updated Phase 2 data from its QUILT-3.078 study in glioblastoma patients. The data showed the primary endpoint of median overall survival had not yet been reached at that time. Shares fell 12.1% to $6.45 on the news.

Business Progress Amid Legal Headwinds

Despite the legal turmoil, ImmunityBio continues to advance its regulatory strategy. On March 9, 2026, the company submitted a supplemental Biologics License Application to the FDA for Anktiva combined with BCG for an additional subgroup of bladder cancer patients. The FDA acknowledged the submission and requested additional efficacy and long-term data, but did not mandate new clinical trials.

In a separate development, Anktiva received regulatory approval in Macau, marking its first clearance in Asia. Authorities there based their decision on prior approvals from the FDA and the European Medicines Agency. The company now markets its products across 34 countries and territories.

These business developments, however, do not directly address the central question of the lawsuit: whether Soon-Shiong's public comments exceeded permissible boundaries and what personal liability he may face as Executive Chairman for those statements.

Ad

ImmunityBio Stock: New Analysis - 05 April

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...